{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'not required for these patients during retreatment. In response to AESIs like anaphylaxis or', 'hypersensitivity, ADA samples closer to the event may be collected and analyzed, based on the', 'judgement of the medical investigator and/or medical monitor.', 'There is no treatment crossover in this study.', '7.1.7.', 'Note Regarding IDMC Interim Analysis 2', 'The Independent Data Monitoring Committee (IDMC) convened on 8 March 2021 to evaluate the', 'data from a planned formal interim analysis of OS. The IDMC declared superiority of os in', 'subjects receiving cemiplimab as compared to IC chemotherapy. As a result of the assessment,', 'Protocol Amendment 7 is being implemented to provide a mechanism for eligible subjects', 'randomized to chemotherapy to receive subsequent cemiplimab as part of the cemiplimab', 'Extension Phase (Section 7.1.7.1).', 'Patients randomized to IC chemotherapy may screen to receive cemiplimab in the cemiplimab', 'Extension Phase up to and including 30 June 2021. Patients previously on IC chemotherapy may', 'receive up to 96 weeks on cemiplimab as per the Schedule of Events for the cemiplimab Extension', 'Phase as per Table 3.', 'All patients currently on cemiplimab may continue treatment up to 96 weeks. All patients', 'receiving cemiplimab will do so as per the Schedule of Events for the cemiplimab Extension Phase', 'as per Table 3.', 'Subjects currently receiving IC chemotherapy (pemetrexed, gemcitabine, topotecan, irinotecan, or', 'vinorelbine) may continue to be treated with IC as long as, in the opinion of the investigator, they', 'are continuing to derive benefit from the assigned treatment. Patients who opt to continue', 'receiving IC chemotherapy will do so as per routine clinical practice.', 'As of Amendment 7, retreatment is no longer an option (Section 7.1.6). As of Amendment', '7,', 'follow-up visits are no longer required (Section 7.1.4).', '7.1.7.1. Cemiplimab Extension Phase of the Study', 'All patients currently on cemiplimab will transition to cemiplimab Extension Phase (Table 3) as', 'of Amendment 7.', 'This section also provides a mechanism for patients randomized to the IC chemotherapy arm to', 'receive cemiplimab 350 mg Q3W.', 'All patients randomized to IC chemotherapy are eligible for crossover to receive cemiplimab in', 'the cemiplimab Extension Phase of the study, as long as eligibility criteria (Section 6.2) are met.', 'Patients with squamous histology or adenocarcinoma/adenosquamous histology may be eligible', 'for the cemiplimab Extension Phase. The following criteria are not exclusionary for patients to', 'enter the cemiplimab Extension Phase of the study:', 'Exclusion criteria #5: Steroids applied as supportive medications for IC chemotherapy', 'will not be exclusionary.', 'Exclusion criteria #20: Patients currently enrolled in R2810-ONC-1676 are not excluded.', 'Patients must complete screening assessments as set forth in Table 3, including signing the ICF.', 'Patients will follow the Schedule of Events in Table 3. Cycle length in the cemiplimab Extension', 'Regeneron Pharmaceuticals, Inc.', 'Page 58 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Phase is approximately 6 weeks, corresponding to two Q3W cemiplimab treatments (+/- 3-day', 'treatment window). The principle of \"time marches on\" applies in the Extension Phase: Treatment', 'not administered in the treatment window will not be made up. Treatment beyond progression is', 'allowed in the cemiplimab Extension Phase if the conditions set forth in Section 8.6 are met.', 'Table 3:', 'Schedule of Events for Cemiplimab Extension Phase', 'Screening', 'Extension', 'Every 3', 'End of', 'Survival', 'Period for', 'Cycle 1/Day', 'weeks, 3', 'Extension', 'Follow-Up4', 'Extension', '1 (EC1D1)', 'days', 'Phase (up to', 'Phase (28 days)', '(EC1D22', '96 weeks)3', '1,2', 'through', '30 days', 'EC16D22)', '7 days after', 'last dose of', 'cemiplimab', 'Inclusion/Exclusi', 'X', 'on', 'Informed', 'X', 'Consent\u00b9', 'Serious Adverse', 'X', 'X', 'X', 'X', 'Events', 'Cemiplimab', 'X', 'X', '350 mg IV', 'Complete', 'X', 'Physical', 'Examination', 'ECOG PS', 'X', 'Limited Physical', 'Exam', 'Vital Signs', 'X', 'Hematology', 'X', 'Blood Chemistry', 'X', 'After the Screening Period, these assessments should be', 'Pregnancy Test', 'X', 'done as clinically appropriate.', 'for WOCBP', 'TSH (with', 'X', 'reflex T3, free', 'T4)', 'CT and/or MRI', 'X', 'Concomitant', 'X', 'Medications', 'Concomitant', 'X', 'Procedures', 'Regeneron Pharmaceuticals, Inc.', 'Page 59 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}